Les 729 meilleurs médecins en Chine

Le Dr Chen Ling est neurologue pédiatrique à l'hôpital Xiamen Humanity. Elle siège au conseil permanent de l'Association anti-épilepsie du Fujian. Le Dr Chen est diplômée de la faculté de médecine de l'université Jiao Tong de Shanghai. Elle a précédemment exercé au premier hôpital affilié de l'université de Xiamen.

• Traite l'épilepsie infantile, les retards de développement et les troubles du tic.
• Prend en charge le TDAH, les infections intracrâniennes et les troubles des nerfs périphériques.
• A suivi une formation en neurologie pédiatrique à l'hôpital Xinhua de Shanghai.
• Siège au conseil de l'Alliance des psychiatres pour enfants et adolescents du Fujian.

Le Dr You Deming est directeur du département de médecine traditionnelle chinoise à l'hôpital Xiamen Humanity. Il est membre permanent du comité du Consortium pour le développement du Tuina pédiatrique en Chine. Le Dr Deming est diplômé de l'Université de médecine traditionnelle chinoise d'Anhui. Il a précédemment exercé au premier hôpital populaire de Bengbu.

• Spécialisé dans la thérapie Tuina pédiatrique et les troubles infantiles courants.
• Traite des pathologies complexes de médecine interne, notamment les troubles rhumatismaux et le diabète.
• Expert en gynécologie MTC et en traitements de l'infertilité.
• Exerce dans un hôpital de soins tertiaires qui traite 1 000 000 de patients par an.

Le Dr Zhang Jin Nong est un expert national en maladies infectieuses à l'hôpital Xiamen Humanity. Il occupe le poste de directeur de la médecine respiratoire et cardiovasculaire. Le Dr Zhang a reçu le prix de l'Individu Avancé de la province du Hubei pour ses efforts dans la lutte contre la pandémie. Il traite des cas complexes de cancer du poumon, de pneumonie et de bronchopneumopathie chronique obstructive.

• Spécialisé dans la bronchoscopie par fibre optique et la ventilation invasive et non invasive.
• Traite les troubles respiratoires liés au sommeil et effectue des tests détaillés de la fonction pulmonaire.
• Sert de directeur adjoint du groupe des maladies infectieuses de l'Association médicale chinoise.
• Occupe un rôle de direction dans la branche de médecine du sommeil de l'Association chinoise contre les accidents vasculaires cérébraux.

Le Dr Yan Zhi Ping occupe le poste de directeur de la radiologie à l'hôpital Xiamen Humanity. Il est spécialisé dans le diagnostic précoce du cancer du poumon et des tumeurs cérébrales. Le Dr Yan a publié plus de 30 articles universitaires et a édité plusieurs monographies professionnelles. Il a reçu le troisième prix de la province du Fujian pour le progrès scientifique et technologique.

• Identifie les maladies du système nerveux central, du système musculo-squelettique et de l'abdomen.
• Expert en tomodensitométrie (TDM), IRM et imagerie fonctionnelle cérébrale.
• Vice-président de la Société de radiologie de Xiamen et de l'Association des médecins de Xiamen.
• Exerce dans un hôpital de soins tertiaires doté du premier centre BNCT de Chine continentale.

La professeure Lydia Chen (Li Ping) est médecin-chef en oto-rhino-laryngologie et chirurgie cervico-faciale. Elle possède plus de 30 ans d'expérience clinique. Ses travaux se concentrent sur la perte auditive soudaine et d'autres troubles de l'oreille. Elle pratique des chirurgies de l'oreille aussi bien microscopiques qu'endoscopiques.

Son expertise couvre des interventions auriculaires telles que la mastoïdectomie, la tympanoplastie, l'ablation de cholestéatome, la réparation de la chaîne ossiculaire et l'excision de fistule préauriculaire. Elle réalise également des adénoïdectomies et des amygdalectomies par technologie plasma, ainsi que de la chirurgie endoscopique des sinus, l'ablation de polypes nasaux et la correction de la déviation de la cloison nasale. Elle assure la rééducation pour la perte auditive, les vertiges otogènes et les acouphènes, et traite les allergies nasopharyngées et laryngées.

Elle est membre de comités tels que l'Association de médecine intégrative du Fujian et l'Association de réadaptation des personnes handicapées du Fujian. Elle collabore également avec l'Association des médecins de Xiamen, l'Association médicale de Xiamen, l'Association de médecine préventive de Xiamen et l'Association de médecine de réadaptation de Xiamen.

Le professeur Zheng Qiu Hong est directeur du Centre de recherche sur la thérapie cellulaire et expert national principal en biothérapie. Il est professeur et superviseur de master à l'Université médicale de Fujian. Il possède plus de 30 ans d'expérience clinique en biologie moléculaire des tumeurs et en biothérapie. De 2012 à 2013, il a été chercheur invité en recherche sur les cellules souches à la School of Life Sciences de l'Université du Connecticut. Il a précédemment occupé des postes de direction à l'hôpital anticancéreux de Fujian, notamment en tant que directeur du laboratoire de biologie moléculaire des tumeurs et directeur du laboratoire de recherche en oncologie chirurgicale. Il a également été directeur adjoint du laboratoire clé de biothérapie tumorale de Fujian et directeur adjoint du centre de biothérapie et d'immunothérapie.

Ses nominations incluent le poste de membre du comité permanent du comité de biothérapie de l'Association chinoise des hôpitaux de recherche. Il est également membre du comité d'immunologie tumorale et de biothérapie de la Société chinoise d'immunologie. De plus, il est vice-président du comité académique du Centre de recherche sur la thérapie cellulaire de Xiamen au premier hôpital affilié de l'Université de Xiamen.

Le professeur Fan Jun Hua est directeur d'ophtalmologie au Xiamen Humanity Hospital. Il possède plus de 20 ans d'expérience clinique. Il se spécialise dans les maladies de la cornée et de la surface oculaire, le glaucome, la cataracte et les traumatismes oculaires. Il a auparavant dirigé le service d'ophtalmologie du Centre d'ophtalmologie de l'hôpital 180 de l'APL. Il a bénéficié de l'allocation pour poste de talent exceptionnel en santé et médecine militaire.

Le Dr Fan a publié plus de 50 articles et a dirigé trois projets militaires ou régionaux. Il a reçu, entre autres distinctions, deux prix de troisième classe pour le progrès scientifique et technologique militaire, deux prix de troisième classe pour les réalisations médicales militaires et deux prix du progrès scientifique et technologique de Quanzhou. Il a été nommé l'un des dix meilleurs gardiens de la santé exceptionnels de Quanzhou. Il est reconnu comme un expert éminent en ophtalmologie par le commandement de la zone militaire de Nanjing et par la province du Fujian.

Dr. Lin Shudian, MD, is Chief Physician and Director of Rheumatology and Immunology. He focuses on autoimmune diseases, especially inflammatory myopathies. He earned his MD in 2007 from Xiangya Hospital, Central South University. He completed advanced rheumatology training at Peking Union Medical College Hospital in 2015. He is Chairman of the Hainan Provincial Rheumatology Association. He is a committee member of the Rheumatology Branches of the Chinese Medical Association and the Chinese Medical Doctor Association. He is Deputy Director of the Hainan Provincial Medical Doctor Association Rheumatology Branch. He is an NSFC reviewer and serves on the editorial board of Hainan Medical Journal.

He has led three projects funded by the NSFC or Hainan Province. He has published more than 10 papers, including four indexed in SCI. He contributed to the translation of Kelley and Firestein’s Textbook of Rheumatology (8th–10th editions). He also helped compile Advanced Clinical Rheumatology, the 2020 China SLE Report, Comprehensive Rheumatology, and Liver-Related Rheumatic Diseases.

Le Dr Ming Shao est professeur, médecin-chef en réadaptation neurologique, chercheur postdoctoral en neurochirurgie et directeur de thèse. Il possède plus de 35 ans d'expérience. Il est spécialisé dans les troubles du mouvement et propose des soins médicaux et chirurgicaux, notamment la stimulation cérébrale profonde, pour la maladie de Parkinson, le tremblement essentiel et la dystonie. Il se concentre également sur la neuroréadaptation et utilise la neuromodulation non invasive pour les accidents vasculaires cérébraux, les lésions de la moelle épinière et les troubles de la conscience.

Il a effectué ses recherches postdoctorales sur le traitement chirurgical de la maladie de Parkinson à l'hôpital Xuanwu de l'Université médicale de la capitale. Il a été sélectionné pour le programme scientifique et technologique « Nova » de Pékin. Il a dirigé plusieurs sous-projets nationaux clés de R&D. Il a publié plus de 60 articles dans des revues majeures. Il a reçu plusieurs prix provinciaux pour ses réalisations scientifiques et technologiques.

Postes : Président du Comité de réadaptation pour la maladie de Parkinson et les troubles du mouvement, Association chinoise de médecine de réadaptation. Membre permanent du conseil, Société chinoise de réadaptation.

Le Dr Wang Jun est un talent médical de premier plan au niveau provincial et professeur à l'hôpital Xiamen Humanity. Il est un expert principal en réadaptation cardiaque et en ostéoporose. Le Dr Wang est spécialisé dans les soins intégrés sino-occidentaux pour les affections gériatriques complexes. Il se concentre sur l'inversion de l'athérosclérose et la prévention des accidents vasculaires cérébraux.

• Identifié comme un talent médical de premier plan dans la province du Fujian.
• Occupe le poste de directeur adjoint pour plusieurs branches régionales de gériatrie et de réadaptation.
• Spécialisé dans l'inversion du diabète et la gestion des soins post-infarctus.
• Travaille dans un hôpital de soins tertiaires traitant 1 000 000 de patients par an.

Le Dr Yu Chang Ying est un expert reconnu en stomatologie à l'hôpital Xiamen Humanity. Il est officiellement désigné comme expert renommé de la province du Fujian. Le Dr Yu est spécialisé dans les implants dentaires et les tumeurs buccales. Il traite les traumatismes buccaux et maxillo-faciaux complexes en situation d'urgence. Le médecin est vice-président de l'Association stomatologique de Xiamen.

• Effectue des implantations dentaires et pose des prothèses sur implants.
• Traite les maladies inflammatoires buccales, les troubles des glandes salivaires et les malformations congénitales.
• Est directeur adjoint du comité des maladies de la muqueuse buccale de l'Association médicale du Fujian.
• Exerce dans un hôpital de soins tertiaires traitant 1 000 000 de patients par an.

Li Guiyuan, MD, is Chief Physician in the Department of Medical Oncology at Shanghai Tongji Hospital. He has practiced oncology since 1996 and has more than 20 years of experience. He earned a master’s degree in Oncology from Nanjing University in 2003. He has worked in the hospital’s Oncology Department since then.

His clinical work includes chemotherapy for lung, breast, ovarian, and gastrointestinal cancers. He also provides targeted and anti‑angiogenic therapies for malignant tumours. He manages malignant pleural and peritoneal effusions and bone metastases with multimodal care, including immunotherapy.

He has authored more than 10 basic and clinical papers, including “Tumour Hypoxia and Its Therapeutic Strategies” and “Establishment of Tumour Model with B16 Melanoma Cell Line of C57BL/6 Mice in ICR Mice.” He received the Medical Achievement Award from the General Logistics Department of the PLA for “Research and Application of Early‑diagnosis and Prediction Model for Metastasis of Non‑small‑cell Lung Cancer.” He co‑authored “Evidence‑based Oncology Treatment” and “Handbook of Modern Evidence‑based Diagnosis and Treatment of Cancer.” He has also taken part in key projects of the National Natural Science Foundation of China.

Le Dr Huang Xue Lei est directeur de la chirurgie orale et maxillo-faciale à l'hôpital Xiamen Humanity. Il est spécialisé dans les tumeurs des glandes salivaires et la réparation complexe des traumatismes de la tête et du cou. Le Dr Huang est titulaire d'un doctorat de l'Hôpital général de l'APL chinoise. Il a également suivi une formation au Neuvième hôpital populaire de Shanghai.

• Membre du comité de la branche de médecine du sommeil de l'Association médicale chinoise.
• Traite le syndrome d'apnée-hypopnée obstructive du sommeil (SAHOS) et les kystes maxillaires.
• Effectue des chirurgies reconstructrices pour les fentes labiales et les cicatrices faciales.
• Directeur adjoint du comité de chirurgie maxillo-faciale de l'Association stomatologique de Xiamen.

La Dre Li Huaifang est spécialisée dans les tumeurs gynécologiques, les troubles du plancher pelvien et la chirurgie gynécologique mini-invasive. Elle a réalisé plus de 10 000 interventions mini-invasives et plus de 5 000 réparations du plancher pelvien. Son travail comprend des opérations oncologiques par laparoscopie et hystéroscopie. Elle pratique également la chirurgie reconstructrice pour le prolapsus et l'incontinence. Elle a fait la démonstration de techniques chirurgicales lors de conférences nationales.

Rôles académiques : Membre national du groupe sur le dysfonctionnement du plancher pelvien (CMA OBGYN). Directrice adjointe du groupe sur le plancher pelvien de l'association d'obstétrique et de gynécologie de Shanghai. Experte au sein du comité de contrôle de la qualité gynécologique de Shanghai. Elle a participé au 12e plan quinquennal. Elle dirige actuellement un sous-projet du 14e plan quinquennal sur les mailles dégradables pour le plancher pelvien. Publications : plus de 240 articles, dont plus de 50 dans des revues SCI. Co-auteure de manuels et superviseure à l'université de Tongji avec plus de 50 étudiants. Parmi ses distinctions, citons le prix de la science et de la technologie médicales de Shanghai, le prix chinois de la science et de la technologie pour la santé maternelle et infantile, ainsi que des prix pour la reconstruction du plancher pelvien en 2006, 2012 et 2015.

Chief Physician. Director and Academic Leader of Gastroenterology at Hainan Provincial People's Hospital. MD and doctoral supervisor. Postdoctoral fellow in Switzerland and visiting scholar in the United States. Focus on diagnosis and personalized treatment of gastrointestinal (GI) tumors, especially neuroendocrine tumors, and precancerous lesions.

Principal investigator of four NSFC projects. Involved in about 30 national studies. Author of over 83 SCI-indexed papers, including 31 as first or corresponding author, with works in PNAS and Clinical Cancer Research. Recipient of the First Prize of the National Science and Technology Progress Award. Holder of five national patents. Contributor to six books (compilation or translation). Key member of the National Clinical Research Center and the National Key Laboratory of Cancer Biology. Holds standing roles in the Chinese Anti-Cancer Association (CACA). Member of the Chinese Medical Association (CMA) Gastroenterology branch and the Digestive Endoscopy collaborative group. Deputy Secretary‑General of the Oncology Branch of the Chinese Geriatrics Society.

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.